MedPath

Tranylcypromine

Generic Name
Tranylcypromine
Brand Names
Parnate
Drug Type
Small Molecule
Chemical Formula
C9H11N
CAS Number
155-09-9
Unique Ingredient Identifier
3E3V44J4Z9
Background

A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders (From AMA Drug Evaluations Annual, 1994, p311).

Tranylcypromine is a racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine with the chiral centers both located on the cylopropane ring. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).

Indication

用于抑郁症。

Associated Conditions
Depressive Episodes
Clinical Trials
Related News

The Effect of Tranexamic Acid in Endoscopic and Microscopic Ear Surgery Cases on Surgeon Satisfaction

Not Applicable
Not yet recruiting
Conditions
Middle Ear Disease
Interventions
Drug: %0.9 Saline
First Posted Date
2024-05-30
Last Posted Date
2024-11-04
Lead Sponsor
TC Erciyes University
Target Recruit Count
100
Registration Number
NCT06434636

Comparison Effectiveness of Rectal Misoprostol & Intravenous Tranexamic Acid Reducing Hemorrhage in Myomectomy

Active, not recruiting
Conditions
Hemorrhage, Surgical
Myoma;Uterus
Effect of Drug
Postoperative Hemorrhage
Postoperative Complications
Interventions
First Posted Date
2023-11-02
Last Posted Date
2023-11-02
Lead Sponsor
Ankara Etlik City Hospital
Target Recruit Count
75
Registration Number
NCT06114758
Locations
🇹🇷

Etlik City Hospital, Ankara, Turkey

Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)

Phase 1
Conditions
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Interventions
First Posted Date
2016-03-24
Last Posted Date
2018-10-18
Lead Sponsor
Michael Luebbert
Target Recruit Count
60
Registration Number
NCT02717884
Locations
🇩🇪

Universitätsklinikum Freiburg, Medical School Freiburg, Freiburg, Germany

🇩🇪

Universitätsklinikum Tübingen, Medical School Tuebingen, Tübingen, Tuebingen, Germany

🇩🇪

Universitätsklinikum Heidelberg, Heidelberg, Baden-Wuerttemberg, Germany

and more 3 locations

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3
Terminated
Conditions
Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders
Interventions
First Posted Date
2015-03-02
Last Posted Date
2018-02-28
Lead Sponsor
Hannover Medical School
Target Recruit Count
407
Registration Number
NCT02374567
Locations
🇩🇪

Bezirkskrankenhaus Augsburg, Augsburg, Germany

🇩🇪

Krankenhaus Hedwigshöhe, Berlin, Germany

🇩🇪

Hannover Medical School, Hannover, Germany

and more 2 locations

Study of TCP-ATRA for Adult Patients With AML and MDS

Phase 1
Completed
Conditions
Acute Myelogenous Leukemia
Myelodysplastic Syndromes
Leukemia
Interventions
First Posted Date
2014-10-23
Last Posted Date
2020-07-21
Lead Sponsor
University of Miami
Target Recruit Count
17
Registration Number
NCT02273102
Locations
🇺🇸

University of Miami, Miami, Florida, United States

Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible

Phase 1
Conditions
AML
Interventions
First Posted Date
2014-10-10
Last Posted Date
2015-07-07
Lead Sponsor
Martin-Luther-Universität Halle-Wittenberg
Target Recruit Count
16
Registration Number
NCT02261779
Locations
🇩🇪

Universitaetsklinikum Halle, Halle, Germany

Interpersonal Psychotherapy for Treatment Resistant Depression

First Posted Date
2013-07-11
Last Posted Date
2013-07-11
Lead Sponsor
Hospital de Clinicas de Porto Alegre
Target Recruit Count
74
Registration Number
NCT01896349
Locations
🇧🇷

Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil

Tranylcypromine Treatment of Bipolar Depression

Phase 4
Completed
Conditions
Bipolar Disorder I or II
Interventions
First Posted Date
2011-09-08
Last Posted Date
2018-03-15
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
7
Registration Number
NCT01430455
Locations
🇺🇸

New York State Psychiatric Institute, New York, New York, United States

PET Biomarkers in Treatment Resistant Depression

Phase 4
Terminated
Conditions
Major Depressive Disorder
Interventions
First Posted Date
2009-12-15
Last Posted Date
2014-09-18
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
13
Registration Number
NCT01031810
Locations
🇺🇸

New York State Psychiatric Institute, New York, New York, United States

Bioavailability Study of Tranylcypromine 10mg Tablets Under Fasting Conditions

Phase 1
Completed
Conditions
To Determine the Bioavailability of Tranylcypromine
Interventions
First Posted Date
2008-04-04
Last Posted Date
2008-04-04
Lead Sponsor
Par Pharmaceutical, Inc.
Target Recruit Count
39
Registration Number
NCT00653393
Locations
🇺🇸

SFBC Ft. Myers, Inc, Ft. Myers, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy